



summit_{plc}

Summit Corporation plc
(“Summit plc” or “the Company”)

BOARD CHANGE

Oxford, UK, 23 January 2009 – Summit Corporation plc (AIM: SUMM), a UK drug discovery company announces that Colin Wall is stepping down as a non-executive director of the Company on 31 January 2009.

This change reduces the size of the Board to seven, four non-executive directors and three executive directors. The directors believe the Board has the requisite balance of skills to manage the future developments of the business.

Barry Price, PhD, Chairman of Summit, commented: “On behalf of the Board, I would like to thank Colin for his contribution to the growth and development of Summit and wish him well for the future.”

- ENDS -

For more information, please contact:

Summit plc

Barry Price, PhD, Chairman

Richard Pye, PhD, Investor Relations

Tel: +44 (0)1235 443951; +44 (0)7825 313476

Citigate Dewe Rogerson

Mark Swallow, PhD / David Dible / Emma Palmer Foster

Tel: +44 (0)207 638 9571

Panmure Gordon

Andrew Burnett / Rakesh Sharma (Corporate Finance)

Ashton Clanfield (Corporate Broking)

Tel: +44 (0)207 459 3600

About Summit plc

Summit plc is a UK based drug discovery company with three parts to its business:

1. Imino sugars

Imino sugars offer a major opportunity for the discovery and development of new drugs in many disease areas. Summit is at the forefront of developing new, second-generation imino sugars and has a focus in two therapeutic areas: anti-infectives and metabolic diseases. The development of Summit's imino sugar platform is the major focus of the Company's research and development activities.

2. Partnered product portfolio

Summit's partnered product portfolio comprises four drug discovery programmes which are the subject of commercial agreements:

- BioMarin Pharmaceuticals: Duchenne muscular dystrophy, SMT C1100 (July 08)
- Orient Pharma: Sialorrhoea, SMT D001 (Sept 08)
- The Lilly TB Drug Discovery Initiative: Tuberculosis (Oct 08)
- Evolva Biotech SA: Infectious diseases associated with bio-terrorism, SMT 14400 (Jan 09)

Summit will make a limited investment into the portfolio as its future development will predominately use the expertise and capital of the respective partners.

3. Services businesses

Summit generates revenues from its two technology platforms in carbohydrate chemistry and zebrafish biology by offering third parties access to them on a fee-for-service or collaborative basis. The cash generated by the businesses contributes to the investment Summit makes into its research and development activities but they operate independently.

The company listed on the alternative investment market (AIM) of the London Stock Exchange in October 2004 - symbol: SUMM. Further information about the company is available at www.summitplc.com.